Commercial-stage biotech Amarin Corporation ( NASDAQ: AMRN ) gained ~13% Monday, the highest intraday gain since June, after the company said that an independent study supported the benefit of purified eicosapentaenoic acid (EPA), a component in its heart disease therapy Vascepa/Vazkepa.
RESPECT-EPA trial funded by the Japanese Heart Foundation marginally achieved statistical significance with a 21.5% reduction in the primary composite endpoint related to cardiovascular risk. It also indicated statistical significance for a 26.6% reduction in the secondary composite endpoint.
Amarin ( AMRN ) said that the RESPECT-EPA was the third study to highlight the beneficial impact of purified EPA in lowering cardiovascular outcomes in patients with coronary artery disease.
The results were part of a presentation at the American Heart Association (AHA) 2022. Other presentations included in vitro data supporting the antioxidant effect of EPA on low-density lipoprotein (LDL) compared to mineral oil.
Vascepa is a fish oil-derived therapy approved in the U.S. for high-risk patients who continue to suffer from cardiovascular risk after statin therapy.
Read: In August, Amarin ( AMRN ) announced new data from its cardiovascular outcomes trial REDUCE-IT, which backed the FDA approval of the treatment in 2019.
For further details see:
Amarin adds 13% as independent study supports heart disease therapy